EMA publishes advice against using ivermectin to treat and prevent coronavirus (COVID-19)

EMA publishes advice against using ivermectin to treat and prevent coronavirus (COVID-19)

The European Medicines Agency (EMA) has published advice against the use of ivermectin for the prevention and treatment of coronavirus (COVID-19). Ivermectin has been approved for treating some parasitic worm infestations, but has not been authorised to use within the EU for treating coronavirus and is not Food and Drug Administration approved. The EMA has reviewed evidence from laboratory studies, clinical trials, meta analyses and observational studies and has concluded that the data does not support the use on ivermectin for coronavirus outside of the controlled clinical trial environment.

Side effects can increase with higher doses of ivermectin, which will be needed to be effective against coronavirus and the toxicity of using ivermectin at higher doses cannot be excluded. The EMA has acknowledged that ivermectin does block the replication of SARS-CoV-2 in vitro, but to see this effect higher concentrations are needed.

Sources:

• EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials

• No ivermectin for COVID, says EMA

Related Articles:
Latest Articles: